TLD isn’t the time to sell regardless. It is after FDA approval, but I agree with your premise. I meant that I may not stick around to see them flop through a launch of this drug on their own. There is a reason most biotech sell out these days, the barriers to entry and successful execution are great. If they can’t pull off an efficient presentation, publication and RA strategy, then they certainly can’t launch well.
If they can pull the first part off, there is hope for them going alone or taking time to negotiate a great deal with a partner. That could obviously take this rocket beyond pre-orbital space and out into the galaxy. So much depends on the next few months and what they have been cooking over the past 3 years.
Are they a ham and egger or are they French cuisine? I honestly don’t know anymore, it could go either way.
Market Data 
Markets 
AI
